查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1660680

2025 年至 2033 年癌症單株抗體市場報告，按抗體類型、藥物類型（貝伐單抗、利妥昔單抗、曲妥珠單抗、西妥昔單抗、帕尼單抗等）、應用、最終用戶和地區分類

Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Others), Application, End-User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球癌症單株抗體市場規模達到 483 億美元。

癌症單株抗體是指實驗室生成的分子，其設計目的在於模仿免疫系統對癌細胞的攻擊。它可以與癌細胞表面的抗原結合併標記它們以觸發細胞膜的破壞、阻止細胞生長和免疫系統抑制劑。它還可以將治療輻射直接傳送到癌細胞以中和或摧毀它們。一些最常用的單株抗體包括鼠抗體、嵌合抗體和人源化抗體，用於治療血液、肝臟、腦部和乳癌。

全球癌症發生率的不斷上升是推動市場成長的關鍵因素之一。與傳統使用的化療等非標靶療法相比，單株抗體對患者身體的副作用較小，也可用於治療自體免疫和發炎性疾病。此外，醫生和腫瘤學家廣泛採用具有成本效益的生物相似藥單株抗體也促進了市場的成長。隨著基因定序和標靶基因選擇技術的進步，這些抗體可以被改造成具有與藥物相似的特性。它們具有相同的功效，但價格比原廠藥更低，有助於提高治療的成本效益，從而促進全球對該產品的需求不斷增加。其他因素，包括對個人化醫療的偏好日益增加、廣泛的研究和開發（R&D）活動以及醫療保健基礎設施的顯著改善，預計將進一步推動市場的發展。

本報告回答的關鍵問題：

  • 全球癌症單株抗體市場迄今表現如何，未來幾年將如何表現？
  • 主要的區域市場有哪些？
  • COVID-19 對全球癌症單株抗體市場有何影響？
  • 根據抗體類型，市場如何分佈？
  • 根據藥物類型，市場如何分佈？
  • 根據應用，市場區隔是怎樣的？
  • 根據最終用戶，市場分佈如何？
  • 該產業的價值鏈分為哪些階段？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球癌症單株抗體市場的結構是怎樣的？
  • 產業的競爭程度如何？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球癌症單株抗體市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第6章：市場細分：依抗體類型

  • 鼠抗體
    • 市場趨勢
    • 市場預測
  • 嵌合抗體
    • 市場趨勢
    • 市場預測
  • 人源化抗體
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按藥物類型

  • 貝伐單抗（阿瓦斯丁）
    • 市場趨勢
    • 市場預測
  • 利妥昔單抗（Rituxan）
    • 市場趨勢
    • 市場預測
  • 曲妥珠單抗（赫賽汀）
    • 市場趨勢
    • 市場預測
  • 西妥昔單抗（Erbitux）
    • 市場趨勢
    • 市場預測
  • 帕尼單抗（Vectibix）
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按應用

  • 乳癌
    • 市場趨勢
    • 市場預測
  • 血癌
    • 市場趨勢
    • 市場預測
  • 肝癌
    • 市場趨勢
    • 市場預測
  • 腦癌
    • 市場趨勢
    • 市場預測
  • 大腸直腸癌
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 醫院和診所
    • 市場趨勢
    • 市場預測
  • 藥局
    • 市場趨勢
    • 市場預測
  • 研究實驗室
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場區隔：依國家
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Roche Holding AG
    • AbbVie Inc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc.
    • Seattle Genetics Inc.
    • Pfizer Inc.
Product Code: SR112025A1955

The global cancer monoclonal antibodies market size reached USD 48.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 65.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033.

A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

Key Market Segmentation:

Breakup by Antibody Type:

  • Murine Antibodies
  • Chimeric Antibodies
  • Humanized Antibodies
  • Others

Breakup by Medication Type:

  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Others

Breakup by Application:

  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Others

Breakup by End-User:

  • Hospitals and Clinics
  • Pharmacies
  • Research Laboratories
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

  • How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?
  • What is the breakup of the market based on the antibody type?
  • What is the breakup of the market based on the medication type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global cancer monoclonal antibodies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Antibody Type

  • 6.1 Murine Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chimeric Antibodies
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Humanized Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Medication Type

  • 7.1 Bevacizumab (Avastin)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Rituximab (Rituxan)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Trastuzumab (Herceptin)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cetuximab (Erbitux)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Panitumumab (Vectibix)
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Blood Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Liver Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Brain Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Colorectal Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Research Laboratories
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Others
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Roche Holding AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AbbVie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Genmab A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 GlaxoSmithKline Plc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Bristol-Myers Squibb Company
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Spectrum Pharmaceuticals Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Seattle Genetics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Pfizer Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
      • 14.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2024
  • Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2024
  • Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2024
  • Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million USD), 2025-2033
  • Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million USD), 2025-2033
  • Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players